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Abstract To understand the epidemiological significance of
Pneumocystis detection in a lung tissue sample of non-
immunosuppressed individuals, we examined sampling pro-
cedures, laboratory methodology, and patient characteristics
of autopsy series reported in the literature. Number of tissue
specimens, DNA-extraction procedures, age and underlying
diagnosis highly influence yield and are critical to understand
yield differences of Pneumocystis among reports of pulmo-
nary colonization in immunocompetent individuals.
Introduction
It is well-known that the fungus Pneumocystis jirovecii dis-
plays tropism for the lungs and causes severe pneumonia in
patients immunocompromised by HIV infection or other
causes of immunosuppression [1]. However, in the broad con-
text, Pneumocystis pneumonia (PCP) is an exceptional event
within the general population; while it is increasingly evident
P. jirovecii colonization is of widespread occurrence and
points to the need to understand significance of this organism
beyond the pneumonia [2–4]. The most common significance
of this mild infection, termed Bcolonization^, is the human-to-
human transmission of the fungus, meaning immunocompe-
tent individuals are likely participants in the circulation of this
pathogen in the community [2, 5, 6]. Transmission studies can
be done using non-invasive respiratory samples. However,
beyond transmission studies, Pneumocystis is no longer con-
sidered a commensal, and clarification of any pathogenic role
of P. jirovecii in the causation of lung disease in immunocom-
petent hosts would greatly benefit from a clearer understand-
ing of the epidemiology of, and tissue distribution of
Pneumocystis in human lung specimens. A pathogenic role
is suggested by the association of P. jirovecii and increased
severity of chronic obstructive pulmonary disease (COPD), by
the detection of increased mucus associated with P. jirovecii in
the lungs of infants dying unexpectedly in the community, and
by the recently described link between P. jirovecii coloniza-
tion and asthma [6–8]. Detection of Pneumocystis in human
lungs is difficult as the organism will not grow in microbial
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culture, adopts a characteristically focal distribution in the
lungs, and requires a specific search using DNA amplification
techniques and/or specific stains that need trained experienced
microscopists to identify the cystic and the more abundant
trophic biological forms. The high prevalence of P. jirovecii
within the general population, and new associations with hu-
man disease that are being described, underscore the impor-
tance of optimizing tissue sampling and standardizing diag-
nostic methodology, which are needed to recognize the epide-
miology and to understand any role of this fungal organism in
lung disease.
A recent publication describing the prevalence of
P. jirovecii colonization in lungs of the general population in
Turkey [3], using DNA amplification techniques, confirms
previous reports detecting Pneumocystis in the autopsied
lungs of immunocompetent individuals from the general pop-
ulation dying in the community in Chile [2, 5] and in the
United States [4], and motivated us to compare the sampling
and diagnostic processes underlying the different yields in
Pneumocystis detection between these studies (Table 1).
Understanding detection methodology is pivotal to compare
epidemiology between countries, and will lead to improved
diagnostic methodologies, to reliable collaborative studies,
and ultimately to reach a better understanding of disease.
Materials and methods
Lung sampling technique
The Chilean series examined between 2 and 15 (median 7)
lung tissue samples, each weighing 0.5 g, representing up to
3% of the weight of the right upper lobe. Pneumocystis-neg-
ative samples were confirmed as negative after analysis of 7%
of lung weight. Magnetic agitation with individually sterilized
magnets was used to homogenize samples [2, 6]. Samples
were centrifuged at 2900 g for 10 min. Özkoç et al. [3] ana-
lyzed a single 1 g sample from the right upper lobe of each
patient. These were mechanically homogenized, and centri-
fuged at a speed of 690 g for 10 min. Beard et al. [4] obtained
four samples (two from each upper lobe) and centrifuged at
14000 g for 5–7 min. The influence of the lower centrifuga-
tion force used by Özkoç et al. on their lower yield for detect-
ing Pneumocystis DNA is difficult to interpret. However,
forces over 1000 g are generally used.
When just the first of all lung samples was analyzed, results
in Chilean samples show that Pneumocystis DNAwas detect-
ed in 16 (29%) of 55 adults with violent deaths, and in 6
(31.5%) of 19 adults dying from medical conditions (Fig. 1).
This yield for detection of Pneumocystis from just the first
analyzed lung sample is still higher when compared to the
12% and 27% reported by Özkoç et al. in samples from
Turkey for violent deaths or for deaths from medical
conditions, respectively (Table 1). Data from Beard et al. is
not available regarding the yield from a single or more than
one lung sample in the US study.
Method used to extract DNA
Vargas et al. used the QIAmp DNA extraction kit (QIAGEN),
Özkoç et al. used theMachery-Nagel extraction kit, and Beard
et al. used the Wizard Genomic DNA purification kit
(Promega). It is not known how these DNA extraction pro-
cesses perform relative to the QIAmp kit. Huggett et al.
showed that the amount of P. jirovecii DNA extracted from
BAL fluid samples was dependant onwhich extraction kit was
used; the yield using QIAmp was higher than that using
DNAeasy [9]. QIAmp recovered more DNA than the
Promega kit for specifically detecting Mycobacterium leprae
on tissue samples [10]. In none of the three studies that are
compared were extracted DNA yield or DNA quality param-
eters documented using A260/280 (yield purity) or A260/230
(quality/contamination) ratios. Amplification reactions in the
Chilean series were run using human β-globin as an internal
control to monitor for DNA-inhibition and liver tissue as a
P. jirovecii-negative control to monitor for cross contamina-
tion. However, no assessments were made to monitor for
DNA yield or quality parameters in any of the manuscripts
reviewed in this article. Promega, Quiagen, and Macherey-
Nagel DNA extraction kits yield amounts of DNA that may
vary depending on elusion volumes according to their manu-
facturer manuals. Interestingly, comparisons of the DNA
amount recovered from the same bronchoalveolar lavage sam-
ples from immunocompromised patients extracted by these
kits as done by Huguet et al. using DNA-easy and QIAamp
favored the QIAamp kit over the DNA-easy kit (12.5-fold
yield versus 2-fold yield) [9]. The potential impact of these
differences in diagnostic sensitivity is unknown and may re-
flect the burden of Pneumocystis in the sample. Whether de-
tection of a very low and focal burden of Pneumocystis organ-
isms, as in lungs from immunocompetent adults, is improved
using a kit that performs favorably in extracting a higher
amount DNA, as indicated in the manufacturer manuals, re-
mains to be determined. We have compared Promega and
Quiagen kits in the same nasopharyngeal aspirate samples
from immunocompetent infants that have a higher
Pneumocystis burden than adults, and, although DNA was
not measured, diagnostic results were consistent for nested-
PCR in these infants (Ponce, CA; unpublished).
DNA amplification protocol
Studies from Chile, Turkey, and the United States amplified
DNA using the multi-copy gene mtLSUrRNA. Consideration
to quantitative PCR protocols should be given in future stud-
ies as they will provide a better estimate of the amount of
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P. jirovecii DNA in a given sample. However, the epidemio-
logical and diagnostic relevance of P. jirovecii quantitation
will need to be documented because a given pulmonary bur-
den of organisms may have a different meaning in different
patient contexts. For example, non-HIV patients with PCP
have paradoxically a lower burden of P. jirovecii organisms
and more severe pneumonia than patients with HIV-related
PCP, therefore indicating that Pneumocystis disease is host
dependent and disease severity does not correlate with
Pneumocystis burden. P. jirovecii colonization of undeter-
mined burden has been associated with old age, or increased
severity of bacterial pneumonia in non-immunosupressed pa-
tients [11]. A major difficulty in interpreting quantitative PCR
is the similar burden levels that can overlap in patients that are
colonized and in patients with PCP [12].
Age of infants studied
Among infants, Vargas et al. [5, 6, 13, 14] and Larsen et al.
[15] have previously shown that detection rates for P. jirovecii
vary by age; with a peak at 2–5 months of age and declining
thereafter. In the study by Özkoç et al., the ages of infants
<12 months of age are not given, but two of 11 infants died
1–2 days after birth, thus inferring that they would be unlikely
to have had time to become heavily colonized withP. jirovecii.
Mode or diagnosis of death
Although a decreased CD4+ T-cell lymphocyte count is the
strongest predictor for Pneumocystis susceptibility, respiratory
disease appears to influence the detection rate of Pneumocystis
among the immunocompetent population in these studies.
Respiratory disease was diagnosed only in the series from
Turkey, where individuals dying from medical conditions had
significantly increased detection of P. jirovecii DNA than those
dying from other causes. Immunosuppressive illnesses were not
diagnosed [2, 3].
Discussion
Amount of lung tissue and tissue distribution
The smaller amount of lung tissue examined may partly ex-
plain the lower yield reported by Özkoç et al. when compared
to results from Chile or from the United States. However,
previous publications also identify distribution of P. jirovecii
in lungs is heterogeneous [16, 17], and a study of immuno-
competent patients with COPD shows that Pneumocystismay
be more abundant in the lower lobes of the lung [7]. The focal
distribution of Pneumocystis determines the need to sample
more than one site to detect colonization. Importantly, in the
Chilean series in adults, no new positives were detected after
seven samples were analyzed (Fig. 1).
Studies in infants from Chile analyzed up to six samples in
infants totaling the same 3% of lung tissue weight as in adults.
These studies used a 0.2-g tissue sample per lung lobe sam-
pling the three right lung lobes. Those infants having at least
one positive sample were considered positive, and negative
infants were sampled a second time for confirmation obtaining
0.4 g from the right upper lobe. A total of 20% of
Pneumocystis-negative infants on first sample changed to pos-
itive after analysis of the second sample, providing a final
Pneumocystis detection rate in infants of 82% [6]. Of interest,
inter-lobe consistency between the three lobes was 59% when
only first sampling analysis was considered, suggesting all
lobes need to be studied [6]. A more recent series analyzing
one, two, or three individual lung tissue samples of 0.4 g each
adding up to 3% of the upper right lung lobe weight give
consistent nested-PCR detection results for each sample, and
negative results do not change after analysis of additional
tissue (Ponce et al., unpublished). Inter-lobar consistency is
being evaluated.
Therefore, the Pneumocystis detection yields in autopsy
samples from Turkey, and from both Chile and the United
States need to be interpreted in the perspective of the number
Table 1 Detection of P. jirovecii DNA from autopsy lung tissue of immune competent adults and infants
Reference Geographical location
Turkey Chile United States
Ref. [3] Ref. [2] Ref. [4]
Patient group No PCR positives for P.jirovecii DNA/No sampled (%)
Adults with cause of death due to violence, suicide, or accident 13/111 (12) 34/55 (62) NA
Adults with cause of death due to an underlying medical condition 20/73a (27) 15/19b (79) NA
Infants, age < 12 months 5/11 (43) 105/128 (82) 58/58 (100)
PCR polymerase chain reaction, NA not applicable
a Diagnoses: cardiovascular conditions includingmyocardial infarction (n = 48), pulmonary infection, edema (n = 14), subarachnoid hemorrhage (n = 7),
pericardial tamponade (n = 2), epileptic seizures (n = 1), and intestinal obstruction (n = 1)
bDiagnoses: myocardial infarction (n = 13), cardiac tamponade (n = 1), stroke (n = 1), subarachnoid hemorrhage (n = 1), digestive hemorrhage (n = 1),
peritonitis (n = 1), and intestinal obstruction (n = 1)
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of samples analyzed. They confirm that the prevalence of
P. jirovecii in autopsy lung material from immunocompetent
adults is high, focal in distribution, and with a very low burden
o f Pneumoc y s t i s o r g a n i sm s a s e v i d e n c e d b y
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immunofluorescence microscopy examination in the Chilean
series [2], and by the negative results of a previous study using
a less sensitive, single-round PCR technique in post-mortem
lungs from non-immunosuppressed individuals 15 to 70 years
of age from the United Kingdom [18].
The lower burden of pulmonary colonization by
Pneumocystis in non-immunosuppressed adult individuals
makes it unlikely that non-invasive sampling will replace the
study of lung specimens for detection of pulmonary coloniza-
tion in the future. Studies using immunosuppressed animals
suggest a correlation of Pneumocystis-DNA results between
non-invasive samples like nasopharyngeal aspirates and lung
tissue samples [19–21]. However, in human adults, a single
diagnostic nasopharyngeal aspirate sample may detect only a
fraction of Pneumocystis upper airway carriers, and sampling
the upper airways more than once may increase the diagnostic
yield for Pneumocystis [22, 23]. This means that a single up-
per airway specimen in adults is not necessarily representative
of lung infection. By contrast, it has been documented that
Pneumocystis-DNA in non-invasive samples from non-
immunocompromised humans may represent nasal carriage
acquired from an external source of contagion, indicating ei-
ther transient or long-term colonization in the upper airways
[23]. Studies that compare the yield of nasopharyngeal aspi-
rate samples, bronchoalveolar lavage samples, and lung sam-
ples in the same individual patients will be difficult to perform
and are lacking. Nasopharyngeal aspirate samples in healthy
immunocompetent adults have an approximate yield of 20%
[24]. A study of bronchoalveolar lavage samples in immuno-
competent individuals undergoing bronchoscopy as part of a
diagnostic work-up for possible respiratory disease in the
United Kingdom, documented that 18% were colonized with
P. jirovecii [25]. The yield of lung tissue samples is higher as
documented in immunocompetent adults in Chile and Turkey,
and detection rate varied depending on sampling procedures.
They documented an average of 65% P. jirovecii-positive
cases in a Chilean series after analysis of a median of seven
specimens of 0.5 g each per lung to amount to 7% of total lung
weight, and an average of 18.5% of P. jirovecii-positive cases
in the series from Turkey after analysis of 1 g of lung tissue
from a single specimen. This suggests that, similar as in non-
invasive sampling [22], the study of multiple autopsy lung
samples increases the yield and is therefore necessary to rec-
ognize the prevalence of the mild and focal pulmonary infec-
tion by Pneumocystis in the non-immunosuppressed adult.
Future autopsy studies in non-immunosuppressed adults
should continue to specify the mode or diagnosis of death,
and include the number of pulmonary samples analyzed, their
total weight, site of origin, precautions to avoid contamina-
tion, DNA extraction method, and gene target amplified, as
essential information for comparison and reproducibility of
results. Future studies in autopsied infant lungs should dis-
close infant ages in addition to the above.
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